TABLE 6.
Overview of potential expenditure and savings (in %) for 2018 based on the five scenarios, broken down by product.
| Medicines | Baseline | Scenario 1: European prices | Scenario 2: Price link—biosimilars | Scenario 3: Price link—all | Scenario 4: RPS—DE | Scenario 5: RPS—Europe | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenditure in. mio. € | Expenditure in. mio. € | Change in % | Expenditure in. mio. € | Change in % | Expenditure in. mio. € | Change in % | Expenditure in. mio. € | Change in % | Expenditure in. mio. € | Change in % | |
| Adalimumab, 20 mg, pre-filled syringe | 1.3 | 0.5 | −62.8 | 1.3 | 0.0 | 1.1 | −14.9 | 1.0 | −25.9 | 0.6 | −50.5 |
| Adalimumab, 40 mg, pre-filled syringe | 507.7 | 200.0 | −60.6 | 506.9 | −0.2 | 432.2 | −14.9 | 320.6 | −36.9 | 244.8 | −51.8 |
| Adalimumab, 40 mg, pre-filled pen | 288.9 | 113.8 | −60.6 | 288.5 | −0.1 | 245.9 | −14.9 | 182.1 | −37.0 | 138.0 | −52.2 |
| Adalimumab 40 mg, vial | 3.1 | 1.1 | −62.8 | 3.1 | 0.0 | 2.6 | −15.0 | 3.1 | 0.0 | 1.6 | −48.8 |
| Adalimumab 80 mg, pre-filled syringe | 9.5 | 3.6 | −62.3 | 9.1 | −3.9 | 7.7 | −18.3 | 9.2 | −2.6 | 5.6 | −41.4 |
| Adalimumab, 80 mg, pre-filled pen | 3.8 | 1.4 | −62.8 | 3.8 | 0.0 | 3.2 | −15.0 | 3.8 | 0.0 | 2.2 | −43.2 |
| Etanercept, 10 mg, pre-filled pen | 0.6 | 0.3 | −54.9 | 0.6 | 0.0 | 0.5 | −15.0 | 0.6 | 0.0 | 0.3 | −50.1 |
| Etanercept, 25 mg, pre-filled syringe | 1.5 | 0.7 | −55.9 | 1.5 | 0.0 | 1.3 | −15.0 | 1.5 | 0.0 | 0.7 | −52.8 |
| Etanercept, 25 mg, pre-filled pen | 30.4 | 13.3 | −56.2 | 30.0 | −1.3 | 25.9 | −14.8 | 24.7 | −18.7 | 14.3 | −53.1 |
| Etanercerpt, 25 mg, vial | 0.1 | 0.0 | −55.9 | 0.1 | 0.0 | 0.1 | −15.0 | 0.1 | 0.0 | 0.0 | −51.7 |
| Etanercept, 50 mg, pre-filled syringe | 260.7 | 113.0 | −56.7 | 243.0 | −6.8 | 224.0 | −14.1 | 234.5 | −10.1 | 132.0 | −49.4 |
| Etanercept, 50 mg, pre-filled pen | 164.7 | 71.6 | −56.5 | 154.4 | −6.3 | 141.4 | −14.2 | 146.8 | −10.9 | 82.7 | −49.8 |
| Infliximab, 100 mg, vial | 306.4 | 129.3 | −57.8 | 273.6 | −10.7 | 254.8 | −16.9 | 298.1 | −2.7 | 210.3 | −31.4 |
| Pegfilgrastim, 6mg, pre-filled syringe | 77.0 | 36.1 | −53.2 | 77.0 | 0.0 | 65.5 | −14.9 | 57.0 | −25.9 | 39.1 | −49.2 |
| Rituximab, 100 mg, vial | 12.2 | 6.3 | −48.5 | 11.1 | −9.2 | 10.2 | −17.0 | 11.4 | −6.7 | 7.9 | −35.6 |
| Rituximab, 500 mg, vial | 11.0 | 6.5 | −41.3 | 11.0 | 0.0 | 9.4 | −15.0 | 11.0 | 0.0 | 7.6 | −31.1 |
| Rituximab, 1.400 mg, vial | 207.1 | 108.6 | −47.5 | 182.8 | −11.7 | 170.1 | −17.9 | 196.5 | −5.1 | 136.6 | −34.1 |
| Trastuzumab, 150 mg, vial | 279.0 | 145.0 | −48.0 | 264.5 | −5.2 | 231.8 | −16.9 | 261.5 | −6.3 | 191.7 | −31.3 |
| Trastuzumab 440 mg, vial | 17.4 | 9.7 | −44.5 | 13.1 | −24.7 | 13.1 | −24.7 | 17.4 | 0.0 | 11.9 | −31.7 |
| Trastuzumab 600 mg, vial | 41.4 | 24.8 | −40.2 | 41.4 | 0.0 | 35.2 | −15.0 | 41.4 | 0.0 | 29.0 | −30.0 |
| Total | 2,223.9 | 985.5 | −55.7 | 2,116.8 | −4.8 | 1,876.0 | −15.6 | 1,822.4 | −18.1 | 1,256.6 | −43.5 |
| Savings (in mio. €) compared to baseline | 1,238.4 | 107.1 | 347.9 | 401.5 | 967.3 | ||||||
Scen. = scenario.
Note: Sums may deviate from totals due to rounding differences.